Eupraxia Pharmaceuticals began trading on Nasdaq’s Global Select Market on September 8, 2026, after transferring from the Nasdaq Capital Market. The Toronto listing remains unchanged, and shareholders need no action. Management will also participate in investor conferences on September 11, September 14, and September 15 and 16.
Key Highlights
- Nasdaq Global Select Market is the exchange’s highest market tier, with financial, Liquidity and governance requirements.
- Eupraxia management will participate in conferences in New York on September 11, September 14, and September 15 and 16.
- EP-104GI is in a Phase 1b RESOLVE trial for eosinophilic esophagitis.
Eupraxia Pharmaceuticals Inc. (NASDAQ: EPRX) began trading on the Nasdaq Global Select Market on September 8, 2026, after moving from the Nasdaq Capital Market. Its Toronto Stock Exchange listing remains unchanged, and shareholders do not need to take action. Eupraxia’s common shares continue to trade under EPRX. Alex Rothwell, Eupraxia’s chief financial officer, said the move reflects the company’s progress and growth. He said Eupraxia remains focused on advancing its clinical programs and creating long-term value for patients and shareholders.
September Investor Conference Schedule Eupraxia
management will take part in the Cantor Global Healthcare Conference on September 11, 2026, in New York, with a fireside chat and one-on-one meetings. The company will present at the H.C. Wainwright 28th Annual Global Investment Conference on September 14, 2026, also in New York, alongside one-on-one meetings. Management will participate in one-on-one meetings at the Morgan Stanley 24th Annual Global Healthcare Conference in New York on September 15 and 16, 2026.
FAQs
Q: When did Eupraxia Pharmaceuticals begin trading on Nasdaq Global Select Market?
A: Eupraxia Pharmaceuticals began trading on the Nasdaq Global Select Market on September 8, 2026. Its common shares continue using the EPRX ticker.
Q: Does the Nasdaq market move require action from Eupraxia shareholders?
A: No action is required from Eupraxia shareholders. The company’s Toronto Stock Exchange listing remains unchanged following the move to Nasdaq Global Select Market.
Q: What investor conferences will Eupraxia Pharmaceuticals attend?
A: Eupraxia management will participate in conferences on September 11, September 14, and September 15 and 16, 2026. The events will take place in New York.
Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research Reports
Disclaimer:
Kalkine Equities LLC, with Delaware File Number 4697384, Foreign Qualification Registration in California File Number 202109211078, and Texas File Number 805521396, is authorized to provide general advice only. The information on https://kalkine.com/ does not take into account any of your investment objectives, financial situation or needs. You should consider the appropriateness of advice taking into account your own objectives, financial situation and needs and seek independent financial advice before making any financial decisions. The link to our Terms and Conditions and Privacy Policy has been provided for your reference. On the date of publishing the reports (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.